ContraVir Pharmaceuticals,Inc. (NASDAQ:CTRV) Files An 8-K Other EventsItem 8.01 Other Events
On August27, 2018, ContraVir Pharmaceuticals,Inc. (the “Company”) filed as Exhibit99.1 to this Current Report on Form8-K a pro forma June30, 2018 balance sheet giving pro forma effect to the receipt of net proceeds from the Company’s rights offering which closed on July3, 2018.
Item 9.01 Financial Statements and Exhibits
(d)Exhibits
|
99.1 |
ContraVir Pharmaceuticals,Inc. pro forma June30, 2018 Balance Sheet |
ContraVir Pharmaceuticals, Inc. ExhibitEX-99.1 2 a18-22003_1ex99d1.htm EX-99.1 Exhibit 99.1 ContraVir Pharmaceuticals,…To view the full exhibit click here
About ContraVir Pharmaceuticals,Inc. (NASDAQ:CTRV)
ContraVir Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development of antiviral drugs for the treatment of Hepatitis B virus (HBV) infections. The Company develops a range of compounds to treat HBV infection, which include CMX157 and CRV431. The Company is also developing an antiviral asset, FV-100. The Company’s CMX157 is a lipid acyclic nucleoside phosphonate that delivers intracellular concentrations of the active antiviral agent tenofovir diphosphate. The Company has completed a Phase I clinical trial of CMX157. The Company’s CRV431 drug candidate is designed to target cyclophilins, which are a class of proteins. CRV431 inhibits the role of host cyclophilins and interferes in the propagation of the viruses. The Company’s FV-100 is an orally available, small molecule, nucleoside analogue pro-drug of CF-1743, which is used for the treatment of herpes zoster. It has developed FV-100 for the treatment of shingles.